Timing of linkage to care after HIV diagnosis and time to viral suppression

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 2, 2016, Pages e57-e60

  Hall, H Irene ^a   Tang, Tian ^a   Johnson, Anna S ^a   Espinoza, Lorena ^a   Harris, Norma ^a   McCray, Eugene ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; RACE DIFFERENCE; SURVIVAL; UNITED STATES; VIRAL LOAD TESTING; VIRUS LOAD; DRUG EFFECTS; ETHNIC GROUP; TIME TO TREATMENT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; TIME-TO-TREATMENT; UNITED STATES; VIRAL LOAD;

EID: 84961231269     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000989     Document Type: Letter

References (11)

1. The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. 2010. Available at: http://www. whitehouse.gov/administration/eop/onap/nhas/. Accessed August 20, 2015.
2. The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: Updated to 2020. 2015. Available at: https://aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Accessed August 20, 2015.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed August 24, 2015.
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365:493-505.
5. Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data-United States and 6 Dependent Areas-2013. HIV Surveillance Supplemental Report 2015. Volume 20 (No. 2). 2015. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed September 14, 2015.
6. Centers for Disease Control and Prevention. High-Impact HIV Prevention: CDC's Approach to Reducing HIV Infections in the United States. Available at: http://www.cdc. gov/hiv/policies/hip.html. Accessed March 17, 2015.
7. Adedinsewo DA, Wei SC, Robertson K, et al. Timing of antiretroviral therapy initiation in a nationally representative sample of HIVinfected adults receiving medical care in the United States. AIDS Patient Care STDS. 2014; 28:613-621.
8. Hall HI, Tang T, Westfall AO, et al. HIV care visits and time to viral suppression, 19 U.S. jurisdictions, and implications for treatment, prevention and the national HIV/AIDS strategy. PLoS One. 2013; 8:e84318.
9. Novak RM, Hart RL, Chmiel JS, et al. Disparities in initiation of combination antiretroviral treatment and in virologic suppression among patients in the HIV Outpatient Study, 2000-2013. J Acquir Immune Defic Syndr. 2015;70:23-32.
10. Liau A, Crepaz N, Lyles CM, et al. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996-2011. AIDS Behav. 2013;17:1941-1962.
11. Centers for Disease Control and Prevention. Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention. Available at: http://www.cdc.gov/hiv/prevention/research/compendium/lrc/index.html. Accessed August 24, 2015.